Insight Molecular Diagnostics (NASDAQ:IMDX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday, Wall Street Zen reports.
IMDX has been the subject of several other research reports. Lake Street Capital decreased their target price on shares of Insight Molecular Diagnostics to $9.00 and set a "buy" rating for the company in a research report on Friday. BTIG Research reaffirmed a "neutral" rating and set a $1.00 price target on shares of Insight Molecular Diagnostics in a report on Wednesday. Stephens reiterated an "equal weight" rating and set a $4.00 price objective on shares of Insight Molecular Diagnostics in a research report on Wednesday. Weiss Ratings reissued a "sell (d-)" rating on shares of Insight Molecular Diagnostics in a report on Monday, September 21st. Finally, Needham & Company LLC reissued a "buy" rating and issued a $9.00 price objective on shares of Insight Molecular Diagnostics in a report on Tuesday, August 18th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $5.75.
View Our Latest Stock Report on Insight Molecular Diagnostics
Insight Molecular Diagnostics Stock Performance
Shares of IMDX opened at $1.95 on Friday. The stock has a fifty day moving average price of $3.05 and a 200 day moving average price of $4.43. Insight Molecular Diagnostics has a 12 month low of $1.50 and a 12 month high of $7.51.
Insight Molecular Diagnostics (NASDAQ:IMDX - Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The company reported ($0.19) earnings per share (EPS) for the quarter. The firm had revenue of $0.56 million for the quarter.
Insider Transactions at Insight Molecular Diagnostics
In other news, major shareholder Broadwood Partners, L.P. purchased 3,428,571 shares of the stock in a transaction dated Tuesday, November 17th. The shares were bought at an average cost of $1.75 per share, for a total transaction of $5,999,999.25. Following the transaction, the insider owned 16,113,455 shares in the company, valued at $28,198,546.25. This trade represents a 27.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 2.21% of the company's stock.
Insight Molecular Diagnostics Company Profile
(
Get Free Report)
Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. NASDAQ: IMDX, is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient's blood to help assess graft health and identify signs of potential injury or rejection. The company's VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company's clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Insight Molecular Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insight Molecular Diagnostics wasn't on the list.
While Insight Molecular Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.